Journal of Hepatology
Volume 51, Issue 5 , Pages 845-852 , November 2009

Reduced serum hepcidin levels in patients with chronic hepatitis C

  • Domenico Girelli

      Affiliations

    • Department of Clinical and Experimental Medicine, University of Verona, Policlinico G.B. Rossi, 37134 Verona, Italy
    • Corresponding Author InformationCorresponding authors. Tel.: +39 045 8124410; fax: +39 045 8027473 (D. Girelli), tel./fax: +39 045 8124205 (G. Fattovich).
    • ,
  • Michela Pasino

      Affiliations

    • Department of Clinical and Experimental Medicine, University of Verona, Policlinico G.B. Rossi, 37134 Verona, Italy
    • Department of Anesthesiological and Surgical Sciences, University of Verona, Verona, Italy
    • ,
  • Julia B. Goodnough

      Affiliations

    • Department of Medicine and Pathology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    • ,
  • Elizabeta Nemeth

      Affiliations

    • Department of Medicine and Pathology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    • ,
  • Maria Guido

      Affiliations

    • Department of Diagnostic Sciences & Special Therapies, University of Padova, Padova, Italy
    • ,
  • Annalisa Castagna

      Affiliations

    • Department of Clinical and Experimental Medicine, University of Verona, Policlinico G.B. Rossi, 37134 Verona, Italy
    • ,
  • Fabiana Busti

      Affiliations

    • Department of Clinical and Experimental Medicine, University of Verona, Policlinico G.B. Rossi, 37134 Verona, Italy
    • ,
  • Natascia Campostrini

      Affiliations

    • Department of Clinical and Experimental Medicine, University of Verona, Policlinico G.B. Rossi, 37134 Verona, Italy
    • ,
  • Nicola Martinelli

      Affiliations

    • Department of Clinical and Experimental Medicine, University of Verona, Policlinico G.B. Rossi, 37134 Verona, Italy
    • ,
  • Italo Vantini

      Affiliations

    • Department of Biomedical and Surgical Sciences, University of Verona, Verona, Italy
    • ,
  • Roberto Corrocher

      Affiliations

    • Department of Clinical and Experimental Medicine, University of Verona, Policlinico G.B. Rossi, 37134 Verona, Italy
    • ,
  • Tomas Ganz

      Affiliations

    • Department of Medicine and Pathology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    • ,
  • Giovanna Fattovich

      Affiliations

    • Department of Anesthesiological and Surgical Sciences, University of Verona, Verona, Italy
    • Corresponding Author InformationCorresponding authors. Tel.: +39 045 8124410; fax: +39 045 8027473 (D. Girelli), tel./fax: +39 045 8124205 (G. Fattovich).

Received 24 March 2009 ,Revised 17 June 2009 ,Accepted 21 June 2009.

References 

  1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558–567
  2. Bialek SR, Terrault NA. The changing epidemiology and natural history of hepatitis C virus infection. Clin Liver Dis. 2006;10:697–715
  3. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35–S50
  4. Bonkovsky HL, Troy N, McNeal K, Banner BF, Sharma A, Obando J, et al. Iron and HFE or Tfr1 mutations as comorbid factors and progression of chronic hepatitis C. J Hepatol. 2002;37:848–858
  5. Beinker NK, Voigt MD, Arendse M, Smit J, Stander IA, Kirsch RE. Threshold effect of liver iron content on hepatic inflammation and fibrosis in hepatitis B and C. J Hepatol. 1996;25:633–638
  6. Chapoutot C, Esslimani M, Joomaye Z, Ramos J, Perney P, Laurent C, et al. Liver iron excess in patients with hepatocellular carcinoma developed on viral C cirrhosis. Gut. 2000;46:711–714
  7. Pietrangelo A. Metals, oxidative stress, and hepatic fibrogenesis. Semin Liver Dis. 1996;16:13–30
  8. Angelucci E, Muretto P, Nicolucci A, Baronciani D, Erer B, Gaziev J, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood. 2002;100:17–21
  9. Guyader D, Thirouard AS, Erdtmann L, Rakba N, Jacquelinet S, Danielou H, et al. Liver iron is a surrogate marker of severe fibrosis in chronic hepatitis C. J Hepatol. 2007;46:587–595
  10. Nahon P, Sutton A, Rufat P, Ziol M, Thabut G, Schischmanoff PO, et al. Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis. Gastroenterology. 2008;134:102–110
  11. Olynyk JK, Reddy KR, Di Bisceglie AM, Jeffers LJ, Parker TI, Radick JL, et al. Hepatic iron concentration as a predictor of response to interferon-alfa therapy in chronic hepatitis-C. Gastroenterology. 1995;108:1104–1109
  12. Lebray P, Zylberberg H, Hue S, Poulet B, Carnot F, Martin S, et al. Influence of HFE gene polymorphisms on the progression and treatment of chronic hepatitis C. J Viral Hepat. 2004;11:175–182
  13. Di Bisceglie AM, Bonkovsky HL, Chopra S, Flamm S, Reddy RK, Grace N, et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology. 2000;32:135–138
  14. Kawamura Y, Akuta N, Sezaki H, Hosaka T, Someya T, Kobayashi M, et al. Determinants of serum ALT normalization after phlebotomy in patients with chronic hepatitis C infection. J Gastroenterol. 2005;40:901–906
  15. Kageyama F, Kobayashi Y, Kawasaki T, Toyokuni S, Uchida K, Nakamura H. Successful interferon therapy reverses enhanced hepatic iron accumulation and lipid peroxidation in chronic hepatitis C. Am J Gastroenterol. 2000;95:1041–1050
  16. Fontana RJ, Israel J, LeClair P, Banner BF, Tortorelli K, Grace N, et al. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, control trial. Hepatology. 2000;31:730–736
  17. Piperno A, Sampietro M, D’Alba R, Roffi L, Fargion S, Parma S, et al. Iron stores, response to α-interferon therapy, and effects of iron depletion in chronic hepatitis C. Liver. 1996;16:248–254
  18. Fargion S, Fracanzani AL, Rossini A, Borzio M, Riggio O, Belloni G, et al. Iron reduction and sustained response to interferon-α therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. Am J Gastroenterol. 2002;97:1204–1210
  19. Kato J, Kobune M, Nakamura T, Kuroiwa G, Takada K, Takimoto R, et al. Normalization of elevated hepatic 8-hydroxy-2′-deoxyguanosine level in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res. 2001;61:8697–8702
  20. Furutani T, Hino K, Okuda M, Gondo T, Nishina S, Kitase A, et al. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology. 2006;130:2087–2098
  21. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology. 1997;25:759–768
  22. Pietrangelo A. Hemochromatosis gene modifies course of hepatitis C viral infection. Gastroenterology. 2003;124:1509–1523
  23. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276:7806–7810
  24. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 2001;276:7811–7819
  25. Pietrangelo A. Hemochromatosis: an endocrine liver disease. Hepatology. 2007;46:1291–1301
  26. Adrews NC. Forging a field: the golden age of iron biology. Blood. 2008;112:219–230
  27. DeDomenico I, McVey Ward D, Kaplan J. Regulation of iron acquisition and storage: consequences for iron-linked disorders. Nat Rev Mol Cell Biol. 2008;9:72–81
  28. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090–2093
  29. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102:783–788
  30. Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control of mammalian iron metabolism. Cell. 2004;117:285–297
  31. Pietrangelo A, Dierssen U, Valli L, Garuti C, Rump A, Corradini E, et al. STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterology. 2007;132:294–300
  32. Camaschella C. Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders. Blood. 2005;106:3710–3717
  33. Harrison-Findik DD, Schafer D, Klein E, Timchenko NA, Kulaksiz H, Clemens D, et al. Alcohol metabolism-mediated oxidative stress downregulates hepcidin transcription and leads to increased duodenal iron transporter expression. J Biol Chem. 2006;281:22974–22982
  34. Bridle K, Cheung TK, Murphy T, Walters M, Anderson G, Crawford DG, et al. Hepcidin is down-regulated in alcoholic liver injury: implications for the pathogenesis of alcoholic liver disease. Alcohol Clin Exp Res. 2006;30:106–112
  35. Nishina S, Hino K, Korenaga M, Vecchi C, Pietrangelo A, Mizukami Y, et al. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology. 2008;134:226–238
  36. Miura K, Taura K, Kodama Y, Schnabl B, Brenner DA. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology. 2008;48:1420–1429
  37. Fujita N, Sugimoto R, Motonishi S, Tomosugi N, Tanaka H, Takeo M, et al. Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion. J Hepatol. 2008;49:702–710
  38. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood. 2008;112:4292–4297
  39. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–699
  40. Deugnier YM, Loreal O, Turlin B, Guyader D, Jouanolle H, Moirand R, et al. Liver pathology in genetic hemochromatosis: a review of 135 homozygous cases and their bioclinical correlations. Gastroenterology. 1992;102:2050–2059
  41. Ludwig J, Hashimoto E, Porayko MK, Moyer TP, Baldus WP. Hemosiderosis in cirrhosis: a study of 447 native livers. Gastroenterology. 1997;112:882–888
  42. Bozzini C, Campostrini N, Trombini P, Nemeth E, Castagna A, Tenuti I, et al. Measurement of urinary hepcidin levels by SELDI-TOF-MS in HFE-Hemochromatosis. Blood Cell Mol Dis. 2008;40:347–352
  43. Cassanelli S, Pignatti E, Montosi G, Garuti C, Mariano M, Campioli D, et al. Frequency and biochemical expression of C282Y/H63D hemochromatosis (HFE) gene mutations in the healthy adult population in Italy. J Hepatol. 2001;34:523–528
  44. Bozzini C, Girelli D, Olivieri O, Martinelli N, Bassi A, De Matteis G, et al. Prevalence of body iron excess in the metabolic syndrome. Diabetes Care. 2005;28:2061–2063
  45. Piperno A, Mariani R, Trombini P, Girelli D. Hepcidin modulation in human disease: from research to clinic. World J Gastroenterol. 2009;15:538–551
  46. Nemeth E, Roetto A, Garozzo G, Ganz T, Camaschella C. Hepcidin is decreased in TFR2 hemochromatosis. Blood. 2005;105:1803–1806
  47. Trinder D, Ayonrinde OT, Olynyk JK. HCV, iron, and oxidative stress: the new choreography of hepcidin. Gastroenterology. 2008;134:348–351
  48. Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood. 2006;108:3204–3209
  49. Verga Falzacappa MV, Vujic Spasic M, Kessler R, Stolte J, Hentze MW, Muckenthaler MU. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood. 2007;109:353–358
  50. Aoki CA, Rossaro L, Ramsamooj R, Brandhagen D, Burritt MF, Bowlus CL. Liver hepcidin mRNA correlates with iron stores but not inflammation, in patients with chronic hepatitis C. J Clin Gastroenterol. 2005;39:71–74
  51. Ferrara F, Ventura P, Vegetti A, Guido M, Abbati G, Corradini E, et al. Serum ferritin as a predictor of treatment outcome in patients with chronic hepatitis C. Am J Gastroenterol. 2009;104:605–616
  52. Deugnier Y, Turlin B, le Quilleuc D, Moirand R, Loréal O, Messner M, et al. A reappraisal of hepatic siderosis in patients with end-stage cirrhosis: practical implications for the diagnosis of hemochromatosis. Am J Surg Pathol. 1997;21:669–675
  53. Detivaud L, Nemeth E, Boudjema K, Turlin B, Troadec MB, Leroyer P, et al. Hepcidin levels in humans are correlated with hepatic iron stores, haemoglobin levels, and hepatic function. Blood. 2005;106:746–748
  54. Fujita N. Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C. Mol Med. 2007;13:97–104
  55. Crosby JR, Gaarde WA, Egerston J, McKay R, Sun YQ, Freier S, et al. Targeting hepcidin with antisense oligonucletides improves anemia endpoints in mice. Blood. 2006;108:83A–84A

☆ This study was funded by NIH (Grant Nos. DK065029 to T.G., K01 DK075378 to E.N., and F30 DK082151 to J.G.). T.G. and E.N. are co-founders and officers of Intrinsic Life Sciences, LLC. The other authors declared that they do not have anything to disclose regarding funding from industries or conflict of interest with respect to this manuscript.

PII: S0168-8278(09)00520-0

doi: 10.1016/j.jhep.2009.06.027

Journal of Hepatology
Volume 51, Issue 5 , Pages 845-852 , November 2009

Article Tools

* Image Usage & Resolution